Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 9/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2691529 | 1.00 | MMP2 (0.41) | MMP2MMP13MMP9MMP8FFAR2 | |
| SCHEMBL2693072 | 0.86 | MMP13 (0.45) | MMP2MMP13MMP9MMP8FFAR2 | |
| SCHEMBL203250 | 0.85 | LMNA (0.38) | MMP13MMP9MMP8MMP1 | |
| SCHEMBL201630 | 0.85 | LMNA (0.38) | MMP13MMP9MMP8MMP1 | |
| SCHEMBL2693629 | 0.85 | MMP8 (0.42) | MMP2MMP13MMP9MMP8FFAR2 | |
| SCHEMBL2693748 | 0.85 | MMP8 (0.42) | MMP2MMP13MMP9MMP8FFAR2 | |
| SCHEMBL2693120 | 0.84 | MMP8 (0.41) | MMP2MMP13MMP9MMP8FFAR2 | |
| SCHEMBL2693118 | 0.81 | MMP2 (0.39) | MMP2MMP13MMP9MMP8FFAR2 | |
| SCHEMBL2693630 | 0.81 | MMP13 (0.39) | MMP2MMP13MMP9MMP8FFAR2 | |
| SCHEMBL13530900 | 0.80 | MMP13 (0.40) | MMP2MMP13MMP9MMP8FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | MMP2 1855/4885MMP13 1654/4885MMP9 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.